- BeyondSpring Inc (NASDAQ:BYSI) announced new data from a study evaluating the reduction in neutropenia burden with lead asset plinabulin in combination with pegfilgrastim in multiple myeloma.
- The study included patients who have undergone autologous hematopoietic stem cell transplantation (AHCT) and have received a high dose of melphalan, a type of chemotherapy.
- Median white blood count on Day 0, 1 and 2 was 7.6 (3.6 – 9.8), 5 (3.2 – 13.6) and 18.7 (5.1-59.1) x 10^9 cells/L, respectively.
- Related: BeyondSpring Cuts On-Third Of Its Workforce.
- Of the eight engrafted patients, the median time to absolute neutrophil count > 0.5 x 10^9 cells/L was 11 days. The median number of days of ANC was <0.1 and <0.5 were two and five days, respectively;
- Six patients had a fever at a median of eight days post-AHCT. Five patients with engraftment syndrome were treated with steroids, and there was one patient with non-engraftment-related neutropenic fever.
- No patients have progressed or died.
- Half of the patients had hypertension immediately after the plinabulin infusion, which is known toxicity and resolved within a few hours.
- Price Action: BYSI shares are up 0.98% at $1.34 on the last check Monday.
BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients
BeyondSpring Inc (NASDAQ:BYSI) announced new data from a study evaluating the reduction in neutropenia burden with lead asset plinabulin in combination…
Related Posts
What’s Going On With AMC Entertainment Stock Wednesday?
AMC Entertainment Holdings Inc (NYSE:AMC) shares continued to see increased volatility this week amid the social media return of GameStop Corp (NYSE:GME) trader Keith Gill, also known as “Roaring Kitty.
Binance Readies Bid For Bankrupt Voyager Again After FTX Downfall: Report
Binance US is reportedly preparing to relaunch a bid for bankrupt lending platform Voyager Digital Ltd (OTC: VYGVF), Coindesk reported, citing a person familiar with the plans.
TreeHouse Foods Reaffirmed FY23 Guidance, Sees Net Sales YoY Growth Of 6%-8%, And Adjusted EBITDA Of $345M-$365M
TreeHouse reaffirmed its previously-issued full year 2023 guidance:
Net sales growth of 6% to 8% year-over-year, which represents a range of $3.66 to $3.73 billion.
Adjusted